EPH150 Post-Market Safety Assessment Associated with JAK Inhibitors of Xeljanz, Olumiant, and Rinvoq Using Faers Database from 2012 to 2022

Abstract

Authors

B Mikaeili AL Hincapie JJ Guo ZA Alqahtani

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×